Orthopediatrics (NASDAQ:KIDS)‘s stock had its “buy” rating reissued by equities research analysts at BTIG Research in a research note issued to investors on Friday, AnalystRatings.com reports. They currently have a $44.00 price target on the stock. BTIG Research’s target price would indicate a potential upside of 6.38% from the stock’s current price.
The analysts wrote, “We maintain our Buy rating and $44 PT following 1Q19 results which saw softer than anticipated Trauma & Deformity sales resulting from weakness in elective deformity procedures. Overall rev. was in-line with BTIG/Street estimates of $14.8M/$14.7M as continued strength in Scoliosis offset T&D softness (~$900k estimated). Despite the 1Q weakness, mgmt. noted that KIDS had not lost share nor seen competitive encroachment and that deformity procedure volumes have come back noticeably in 2Q to date. That said, at KIDS’ multiple we feel shares will be pressured at least until the bounce-back in volume is seen in 2Q. We continue to view a significant market opportunity, a robust pipeline (both organically and inorganically), and limited competition as able to support continued 20%+ growth (here).””
Several other research analysts have also recently weighed in on the stock. BidaskClub raised shares of Orthopediatrics from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Zacks Investment Research raised shares of Orthopediatrics from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Saturday, March 16th. Finally, JMP Securities began coverage on shares of Orthopediatrics in a report on Wednesday, February 20th. They set an “outperform” rating and a $44.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Orthopediatrics currently has a consensus rating of “Buy” and a consensus target price of $41.00.
Orthopediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Orthopediatrics had a negative net margin of 20.89% and a negative return on equity of 22.99%. The company had revenue of $14.66 million for the quarter, compared to analysts’ expectations of $14.67 million. As a group, equities research analysts forecast that Orthopediatrics will post -0.41 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. American International Group Inc. raised its holdings in shares of Orthopediatrics by 10.2% during the first quarter. American International Group Inc. now owns 5,025 shares of the company’s stock valued at $222,000 after purchasing an additional 465 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Orthopediatrics by 6.6% during the first quarter. Rhumbline Advisers now owns 9,350 shares of the company’s stock valued at $414,000 after purchasing an additional 580 shares during the last quarter. We Are One Seven LLC purchased a new position in shares of Orthopediatrics during the fourth quarter valued at approximately $39,000. California State Teachers Retirement System raised its holdings in shares of Orthopediatrics by 12.5% during the first quarter. California State Teachers Retirement System now owns 12,209 shares of the company’s stock valued at $540,000 after purchasing an additional 1,361 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Orthopediatrics by 83,150.0% during the first quarter. BNP Paribas Arbitrage SA now owns 1,665 shares of the company’s stock valued at $74,000 after purchasing an additional 1,663 shares during the last quarter. 44.89% of the stock is owned by hedge funds and other institutional investors.
Orthopediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Featured Story: What are defining characteristics of a correction?
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.